Michele Pellegrini

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Physical Activity

Top Venues

Human vaccines & immunotherapeutics

Open forum infectious diseases

PLoS neglected tropical diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Venanzio Vella, Dominique Derreumaux, Emmanuel Aris, Michele Pellegrini, Mario Contorni, Mikhail Scherbakov, Fabio Bagnoli
The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020. Open forum infectious diseases 11 (6) (2024)
Venanzio Vella, Dominique Derreumaux, Emmanuel Aris, Michele Pellegrini, Mario Contorni, Mikhail Scherbakov, Fabio Bagnoli
The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020. Open forum infectious diseases 11 (6) (2024)
Puneet Vir Singh, Paola Tiberi, Gabriele Filippo Di Domenico, Valerio Romolini, Thembile Mzolo, Marco Costantini, Tauseefullah Akhund, Venere Basile, Maria Lattanzi, Michele Pellegrini
Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis. Drug safety (2022)
Javier Diez-Domingo, Juan Carlos Tinoco, Airi Poder, Ener Cagri Dinleyici, Haylene Nell, Ignacio Salamanca de la Cueva, Tolga Ince, Edson Duarte Moreira Júnior, Khatija Ahmed, Kleber Luz, Yulia Kovshirina, Carlos Eduardo Medina Pech, Tauseefullah Akhund, Valerio Romolini, Marco Costantini, Thembile Mzolo, Barry Kunnel, Isabelle Lechevin, Marianna Aggravi, Paola Tiberi, K Narendran, Juan-Antonio Garcia-Martinez, Venere Basile, Elena Fragapane, Maria Lattanzi, Michele Pellegrini
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults. Human vaccines & immunotherapeutics (2021)
Federico M Torres, Muhamed-Kkeir Taha, Markus Knuf, Victoria Abbing-Karahagopian, Michele Pellegrini, Rafik Bekkat-Berkani, Véronique Abitbol
Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations. Pathogens and global health (2021)
Marzia Monica Giuliani, Alessia Biolchi, Pavitra Keshavan, Maria Moriondo, Sara Tomei, Laura Santini, Elena Mori, Alessandro Brozzi, Margherita Bodini, Francesco Nieddu, Silvia Ricci, Thembile Mzolo, Marco Costantini, Chiara Azzari, Michele Pellegrini
Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children. Human vaccines & immunotherapeutics 17 (5) (2020)
Hoan-Jong Lee, Dae Sun Jo, Yun Kyung Kim, Hyunju Lee, Kyung Hyo Kim, Dokyung Lee, Carlo Curina, Marco Costantini, Silvia Barbi, Yan Miao, Michele Pellegrini
One-year antibody persistence and safety of a 4-dose schedule of MenACWY-CRM in healthy infants from South Korea. Clinical and experimental vaccine research 8 (2) (2019)
Yan Miao, Thembile Mzolo, Michele Pellegrini
Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial. Infectious diseases and therapy 8 (3) (2019)
Byung Wook Yoo, Hye Lim Jung, Yoon Seob Byeon, Dong Ki Han, Nak Yeong Jeong, Carlo Curina, Luca Moraschini, Sung Jin Kim, Chiranjiwi Bhusal, Michele Pellegrini, Yan Miao
Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years. Human vaccines & immunotherapeutics 16 (6) (2019)
Phirangkul Kerdpanich, Pornthep Chanthavanich, Mari Rose De Los Reyes, Jodor Lim, Delia Yu, Ma Cecilia Ama, Zenaida Mojares, Daniela Casula, Ashwani Kumar Arora, Michele Pellegrini
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults. PLoS neglected tropical diseases 12 (6) (2018)